|
1
|
Won HS, Chun SH, Kim BS, Chung SR, Yoo
IeR, Jung CK, Kim YS, Sun DI, Kim MS and Kang JH: Treatment outcome
of maxillary sinus cancer. Rare Tumours. 1(e36)2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Praveena NM and Maragathavalli G:
Carcinoma of the maxillary antrum: A case report. Cureus.
10(e2614)2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dulguerov P, Jacobsen MS, Allal AS,
Lehmann W and Calcaterra T: Nasal and paranasal sinus carcinoma:
Are we making progress? A series of 220 patients and a systematic
review. Cancer. 92:3012–3029. 2001.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dooley L and Shah J: Management of the
neck in maxillary sinus carcinomas. Curr Opin Otolaryngol Head Neck
Surg. 23:107–114. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ashraf M, Biswas J, Dam A, Bhowmick A, Jha
Sing V and Nayak S: Results of treatment of squamous cell carcinoma
of maxillary sinus: A 26-year experience. World J Oncol. 1:28–34.
2010.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Noronha V, Patil VM, Joshi A, Krishna MV,
Dhumal S, Juvekar S, Pai P, Chatturvedi P, Chaukar DA, Agarwal JP,
et al: Induction chemotherapy in technically unresectable locally
advanced carcinoma of maxillary sinus. Chemother Res Pract.
2014(487872)2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Xiang JJ, Uy NF, Minja FJ, Verter EE and
Burtness BA: Hyperprogression after one dose of nivolumab in
sinonasal cancer: A case report. Laryngoscope. 130:907–910.
2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Yazici G, Gullu I, Cengiz M, Elmali A,
Yilmaz MT, Aksoy S, Yuce Sari S and Ozyigit G: The synergistic
effect of immune checkpoint blockade and radiotherapy in
recurrent/metastatic sinonasal cancer. Cureus.
10(e3519)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Guram K, Nunez M, Einck J, Mell LK, Cohen
E, Sanders PD, Miyauchi S, Weihe E, Kurzrock R, Boles S and Sharabi
AB: Radiation therapy combined with checkpoint blockade
immunotherapy for metastatic undifferentiated pleomorphic sarcoma
of the maxillary sinus with a complete response. Front Oncol.
8(435)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Rose TL, Harrison MR, Deal AM, Ramalingam
S, Whang YE, Brower B, Dunn M, Osterman CK, Heiling HM, Bjurlin MA,
et al: Phase II study of gemcitabine and split-dose cisplatin plus
pembrolizumab as neoadjuvant therapy before radical cystectomy in
patients with muscle-invasive bladder cancer. J Clin Oncol.
39:3140–3148. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Emens LA and Middleton G: The interplay of
immunotherapy and chemotherapy: Harnessing potential synergies.
Cancer Immunol Res. 3:436–443. 2015.PubMed/NCBI View Article : Google Scholar
|
